Tourmaline Bio (TRML) Stock Price, News & Analysis

Company Overview

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Key Stats

• Today's Range: $47.57 to $47.69
• 50-Day Range: $15.96 to $47.64
• 52-Week Range: $11.56 to $47.69
• Volume: 22.67 million shs
• Average Volume: 207,788 shs
• Market Capitalization: $1.22 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.19
• Consensus Rating: Moderate Buy

Tourmaline Bio Stock Analysis - MarketRank™

Tourmaline Bio scored higher than 27% of companies evaluated by MarketBeat, and ranked 607th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tourmaline Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Tourmaline Bio is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Tourmaline Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tourmaline Bio is -13.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tourmaline Bio is -13.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tourmaline Bio has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.02% of the float of Tourmaline Bio has been sold short.

Short Interest Ratio / Days to Cover

Tourmaline Bio has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Tourmaline Bio has recently decreased by 4.94%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tourmaline Bio does not currently pay a dividend.

Dividend Growth

Tourmaline Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.02% of the float of Tourmaline Bio has been sold short.

Short Interest Ratio / Days to Cover

Tourmaline Bio has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Tourmaline Bio has recently decreased by 4.94%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.00

News Sentiment

Tourmaline Bio has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Tourmaline Bio this week, compared to 4 articles on an average week.

Search Interest

10 people have searched for TRML on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Tourmaline Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tourmaline Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.00% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TRML Stock Analysis - Frequently Asked Questions

How have TRML shares performed this year?

Tourmaline Bio's stock was trading at $20.28 at the start of the year. Since then, TRML stock has increased by 134.9% and is now trading at $47.64.

How were Tourmaline Bio's earnings last quarter?

Tourmaline Bio, Inc. (NASDAQ:TRML) issued its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.94) by $0.04.

Who are Tourmaline Bio's major shareholders?

Top institutional shareholders of Tourmaline Bio include QVT Financial LP (8.39%), Balyasny Asset Management L.P. (2.35%), Nantahala Capital Management LLC (2.17%) and Geode Capital Management LLC (1.82%). Insiders that own company stock include Mark Mcdade, Parvinder Thiara, Aaron Kantoff and Sandeep Chidambar Kulkarni.
View institutional ownership trends.

How do I buy shares of Tourmaline Bio?

Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tourmaline Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/09/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRML
• Previous Symbol: NASDAQ:TRML
• CIK: 1827506
• Web: N/A
• Phone: 502-398-9250
• Fax: N/A
• Employees: 44
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tourmaline Bio: $50.86
• High Price Target: $70.00
• Low Price Target: $25.00
• Potential Upside/Downside: +6.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$73.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -30.50%
• Return on Assets: -29.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.68
• Quick Ratio: 24.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.71 per share
• Price / Book: 4.07

Miscellaneous

• Outstanding Shares: 25,692,000
• Free Float: 22,352,000
• Market Cap: $1.22 billion
• Optionable: Optionable
• Beta: 2.04